The BCD-132-4/MIRANTIBUS clinical study will evaluate and compare the efficacy of BCD-132 and teriflunomide in patients with multiple sclerosis who:
Are diagnosed with multiple sclerosis.
Are aged 18 to 60 years.
Participation of a maximum of 338 people in the Russian Federation has been approved for this study.
The BCD-132-4/MIRANTIBUS study takes place at 30 study centers in Moscow, Saint Petersburg, and other cities in the Russian Federation.
You can ask questions about participation in the clinical study and request contact information about study centers using a special form «Do you have any questions?».
Authorization of the Ministry of Health of the Russian Federation for this clinical study, No. 106 dated February 25, 2021, and the list of approved study centers have been published in the State Register of Medicines.